Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)

BACKGROUND: ALL is the most frequent hematological tumor in children, so during remission induction chemotherapy protocol (RICP) adverse events (AEs) may appear. The public program in Mexico in charge of financial support to oncologic children without social security delivered a fix amount for ALL c...

Descripción completa

Detalles Bibliográficos
Autores principales: Mejía-Aranguré, Eréndira, Reyes-López, Alfonso, Juárez-Villegas, Luis Enrique, Hernández-Olivares, Yosef Olaf, Saucedo-Campos, Alberto Daniel, Hernández-Pliego, Gabriela, Martínez-Valverde, Silvia, Barajas-Nava, Leticia A., Garduño-Espinosa, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749331/
https://www.ncbi.nlm.nih.gov/pubmed/36517861
http://dx.doi.org/10.1186/s12913-022-08676-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749331/
https://www.ncbi.nlm.nih.gov/pubmed/36517861
http://dx.doi.org/10.1186/s12913-022-08676-x

Ejemplares similares